The China Osteoporosis therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
China has the largest old-aged population around the world, and the incidence rate of osteoporosis keeps increasing year after year. The number of patients diagnosed with osteoporosis in China is over 70 million, and the number of female patients is triple as much as that of male patients. 40%-50% of patients are 60 years old or above, and about 25% of patients have suffered fractures because of osteoporosis. The incidence of fracture, pain and deformation of the spinal column keeps increasing.
The major factor accrediting to the growth of the market is increasing the incidence of osteoporosis. The rising geriatric population globally who are prone to low bone density is another main factor for the growth of the market. Furthermore, the growing investments in research and development by biotechnology and pharmaceutical companies are boosting the market growth. The rate of osteoporosis is more prevalent in women when it comes to men and further in the post-menopause stage in their life.